08:00 , Jan 12, 2015 |  BioCentury  |  Emerging Company Profile

Neutralizing RNAi

The negatively charged phosphate backbone of RNA is critical for the oligonucleotide's biological activity but also prevents its uptake into cells and limits its circulating half-life. Solstice Biologics LLC's ribonucleic neutrals platform could enable efficient...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Financial News

Curetis financial update

Curetis AG, Holzgerlingen, Germany   Business: Diagnostic   Date announced: 2014-11-24   Note: Curetis raised €14.5 million ($18 million) in an extension of a series B financing, bringing the total raised to €27 million ($34.3 million). New investors...
01:33 , Sep 13, 2014 |  BC Extra  |  Financial News

Affimed raises $56M in IPO

Affimed Therapeutics B.V. (NASDAQ:AFMD) was down $1.30 to $5.70 on its first day of trading Friday after raising $56 million through the sale of 8 million shares at $7 in an IPO. The IPO price...
01:20 , Sep 3, 2014 |  BC Extra  |  Financial News

Affimed sets IPO terms, raises series E

Cancer immunotherapy company Affimed Therapeutics AG (Heidelberg, Germany) set the terms for a planned IPO on NASDAQ and also said it closed a EUR 11.7 million ($15.4 million) series E round. The company plans to...
07:00 , Jun 16, 2014 |  BioCentury  |  Finance

Legal tracks

Legal tracks Rüdiger Herrmann joined Dechert LLP's life sciences practice in Frankfurt. Venture tracks Lou Tartaglia left Third Rock Venturesto become president, CEO and a director of RNAi company Solstice Biologics LLC. Solstice's investors include venBio and Aeris...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Financial News

GenomeDx Biosciences completes venture financing

GenomeDx Biosciences Inc., Vancouver, B.C.   Business: Diagnostic   Date completed: 9/30/13   Type: Venture financing   Raised: Not disclosed   Investors: Merck Global Health Innovation Fund; Baird Venture Partners; Aeris Capital AG; CD Ventures   ...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

Deciphering GenomeDx

Deciphering GenomeDx While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences Inc. shows there is money out there for companies with a path to reimbursement. The size of the round is...
00:47 , Oct 1, 2013 |  BC Extra  |  Financial News

GenomeDx closes series B round

Molecular diagnostic company GenomeDx Biosciences Inc. (Vancouver, B.C.) raised an undisclosed amount in a series B round led by new investor Merck Global Health Innovation Fund and a new undisclosed investor. Existing investors Baird Venture...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Financial News

Affimed completes venture financing

Affimed Therapeutics AG, Heidelberg, Germany   Business: Cancer, Inflammation, Antibodies   Date completed: 7/15/13   Type: Venture financing   Raised: $14 million   Investors: MPM Capital; Aeris Capital; Affimed Therapeutics AG   Note: Affimed's Amphivena Therapeutics Inc. subsidiary closed a series...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Affimed board of directors update

Affimed Therapeutics AG, Heidelberg, Germany   Business: Cancer, Inflammation, Antibodies   Appointed: Luke Evnin, managing director of MPM Capital, as a director of Affimed's Amphivena Therapeutics Inc. subsidiary; Phil Gutry, principal at MPM Capital, as a director...